Беротек Н – новая форма бесфреонового дозированного аэрозольного ингалятора

1. Бронхиальная астма. Глобальная стратегия. Национальный Институт Сердце, Легкие и Кровь. Издание № 95-3659. Январь 1995. Русская версия под редакцией акад. А.Г.Чучалина. Пульмонология 1996; Прил.

2. The British guidelines on asthma management. Thorax 1998; 52: suppl. 1.

3. Чучалин Л.Г., Медников Б.Л., Белевский A.C. и др. Бронхиальная астма. Руководство для врачей России. (Формулярная система). Пульмонология 1999; Прил.

4. Хронические обструктивные болезни легких. Федеральная программа. М.; 1999.

5. Huchon G. Metered dose inhalers: past and present: advantages and limitations. Eur. Respir. Rev. 1997; 41: 26-28.

6. Цой Л.Н. Преимущества и недостатки приспособлений для индивидуальной ингаляционной терапии. Пульмонология 1997; 3: 71-74.

7. Огородова JI.M. Системы ингаляционной доставки препаратов в дыхательные пути. Там же 1999; 1: 84-87.

8. Matthys И. CFCs and their effect on the ozone layer: the Montreal protocol and consequences for physicians. Eur. Respir. Rev. 1997; 7: 29-31.

9. Boulet L.P. The ozone layer and metered dose inhalers. Can. Respir. J. 1998; 5: 176-179.

10. Chronic Obstructive Pulmonary Disease (COPD) is a major health and socioeconomic burden; one of the top five causes of disability and death in industrial societies. Personal communication: http://www.boehringer-ingelheim.com.

11. Ensuring patient care. The role of the HFC MDI. 2nd ed. Washington, D. C.: IPAC; 1999.

12. Goldberg J., Schmidt P., Freund E. et al. 12-week safety and efficacy study of fenoterol hydrobromide MDI formulated with HFA 134a or CFC in patients with asthma. Personal communication: http://www.boehringer-ingelheim.com.

13. Vermeulen J., Boshof L., Lowe L.S. et at. Fenoterol delivered via HFA metered dose inhaler (MDI) is as safe and effective as CFC delivery in the long-term treatment of children with asthma. Eur. Respir. J. 1999; 14 (suppl. 30): 180S, abstr. P1267.

14. Leclerk V., Thebablt J.J., Iacono P. et al. Dose-response to fenoterol MDI with non-CFC propellant HFA 134a is equivalent to CFC-MDI in patients with asthma. Personal communication: http://www.boehringer-ingelheim.com.

15. Huchon G., Hofbaner P., Cannizaro G. et at. Comparison of the safety of drug delivery via HFA- and CFC-metered dose inhalers in CAO. Eur. Respir. J. 2000; 15: 663-669.

16. "Anwendungsbeobachtug". Personal communication: http://www.boehringer-ingelheim.com.

17. Bateman E.D., Joubert L.R., Le Roux A.M. et al. Therapeutic equivalence of MDI formulation study in patients with asthma. Eur. Respir. J. 1997; 10 (suppl. 25): 240S, abstr. P1542.

18. Joubert J.R., Bateman E.D., Le Roux A.M. et al. Therapeutic equivalence of MDI formulations of fenoterol with HFA or CFC propellants: a dose confirmation study in patients with asthma. Personal communication: http://www.boehringer-ingelheim.com.

19. June D. Achieving the change: challenges and successes in the formulation of CFC-free MDIs. Eur. Respir. Rev. 1997; 7 (41): 32-34.

20. Zoidis J.D. Your metered-dose inhaler will be changing. RT Magazine 1998; 11: 27-35.

21. Molina M.J., Rowland F.S. Stratospheric sink for chlorofluoromethanes, chlorine atom-catalyzed destruction of ozone. Nature 1974; 249: 810-817.

22. Stolarski R.S., Cicerone R.J. Stratospheric chlorine: a possible sink for ozone. Can. J. Chem. 1974; 52: 1610-1624.

23. Montreal protocol on substances that deplete the ozone layer (Sept. 16, 1987. 26: ILM 1541). Montreal; 1987.